Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Corey Davis – LifeSci AdvisorsScott Struthers – Founder and Chief Executive OfficerAlan Krasner – Chief EndocrinologistMarc Wilson – Chief Financial OfficerJim Hassard – Chief Commercial Officer Conference Call Participants Yasmeen Rahimi – Piper SandlerJessica Fye – JPMorganCory Jubinville…
Rhythm Pharmaceuticals, Inc (NASDAQ:RYTM) Q1 2024 Results Conference Call May 7, 2024 8:00 AM ET Company Participants David Connolly – Executive Director, IR and Corporate CommunicationsDavid Meeker – Chairman, President, and CEOJennifer Lee – Executive Vice President, Head of North AmericaYann Mazabraud – Executive Vice President, Head of InternationalHunter Smith – Chief Financial Officer Conference…
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q1 2024 Results Earnings Conference Call May 3, 2024 8:30 AM ET Company Participants Tony DiMeo – Head of Investor RelationsChirag Patel – President and Co-Chief Executive OfficerChintu Patel – Co-Chief Executive OfficerTasos Konidaris – Executive Vice President and Chief Financial OfficerJoe Renda – Senior Vice President, Chief Commercial Officer, Specialty…
D3Damon/E+ via Getty Images Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is a biotechnology company that stands out in advancing DNA-based immunotherapies and primarily focuses on conditions related to Human papillomavirus (HPV), various cancers, and infectious diseases. INO leverages cutting-edge technologies like SynCon DNA plasmids and CELLECTRA electroporation delivery. INO’s technologies permit the development of a broad range…
Editor’s note: Seeking Alpha is proud to welcome Pivotal Biotech as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » Hiroshi Watanabe Summary On…
Martin Barraud/OJO Images via Getty Images Vertex Pharmaceuticals (NASDAQ:VRTX) announced yesterday it will acquire Alpine Immune Sciences (NASDAQ:ALPN) for $65 per share, which translates to $4.9 billion market value or $4.6 billion net of cash. Vertex is gaining povetacicept, a phase 3-ready clinical candidate for the treatment of IgA nephropathy with pipeline in a drug…
Andrii Yalanskyi/iStock via Getty Images This is my sixth Catalyst (NASDAQ:CPRX) article. I rated it as a tepid “Buy” in my most recent 07/2023’s “Catalyst Pharmaceuticals: A New Catalyst Tilts The Scales – Just Barely” (“Just Barely“). Since Just Barely, Catalyst has performed well, up ~20%. The thesis of Just Barely pegged Catalysts as a…
adventtr Shares of gene therapy concern Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) have risen by 20% since we last looked at it in May of last year, as the company is poised for two potential FDA approvals. Furthermore, its one potential blockbuster rare disease gene therapy, RP-A501 for the treatment of Danon Disease, began enrolling patients in…
fatido/E+ via Getty Images Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is an ideal biotech to keep an eye on this year. That’s because it has made advancements on several fronts in terms of possible regulatory approvals for its gene therapies. In particular, just today, it noted that the European Medicines Agency [EMA] just accepted its regulatory application…
koto_feja Investment Overview In a note for Seeking Alpha in May last year, I gave Longboard Pharmaceuticals (NASDAQ:LBPH) a “Buy” recommendation, citing upcoming data catalysts for the company’s two clinical stage assets – the 5-HT2C Superagonist LP352, now known as bexicaserin, being developed to treat developmental and epileptic encephalopathies (DEEs), and LP659 – and a…
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Conference Call March 7, 2024 8:30 AM ET Company Participants Eric Sciorilli – Head of Investor Relations Terrie Curran – President & Chief Executive Officer Martin Gilligan – Chief Commercial Officer Molly Henderson – Chief Financial Officer Azmi Nabulsi – Chief Operating Officer Conference Call Participants Yatin Suneja…
Daniel Grizelj/DigitalVision via Getty Images Introduction Avadel Pharmaceuticals plc‘s (NASDAQ:AVDL) stock is up 51% since my “Buy” recommendation in November, and we’ve had a couple of key updates that took place on Monday. Seeking Alpha First, the company reported Q4 earnings. Then, a jury awarded Jazz Pharmaceuticals plc (JAZZ) a 3.5% royalty rate on Avadel’s…
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2023 Earnings Conference Call March 4, 2024 7:30 AM ET Company Participants Austin Murtagh – Stern IR Gregory Divis – CEO Richard Kim – Chief Commercial Officer Thomas McHugh – CFO Conference Call Participants Francois Brisebois – Oppenheimer Ami Fadia – Needham Andrew Tsai – Jefferies David Amsellem – Piper…
Dr_Microbe Fusion Pharmaceuticals (NASDAQ:FUSN) emerges as an interesting story in the oncology sector, especially in the niche but growing radiopharmaceuticals segment. The appeal of Fusion lies in its approach to precision oncology, particularly with its clinical candidates’ portfolio for a range of cancers. The company’s investment attractiveness is anchored by its commitment to innovation, including…
ktsimage Strategic Acceleration: Rocket Pharmaceuticals’ RP-A501 For Danon Disease Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock is up 76% since my “Buy” recommendation in August. The stock shot up in September on the heels of a public offering and some other news. Interestingly, the FDA and Rocket reached an agreement supporting the potential for accelerated approval based…
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Sharon Klahre – Head, Investor Relations Michael Metzger – Chief Executive Officer Dr. Neil Gallagher – President and Head, R&D Keith Goldan – Chief Financial Officer Dr. Peter Ordentlich – Chief Scientific Officer Dr. Anjali Ganguli – Chief…
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Al Kildani – Senior Vice President, Investor Relations and Corporate Communications Steve Davis – President and Chief Executive Officer Brendan Teehan – Executive Vice President, Chief Operating Officer, Head of Commercial Doug Williamson – Executive Vice President, Head…
Andriy Onufriyenko/Moment via Getty Images Investment Overview Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the Carlsbad, California-based, commercial stage pharmaceutical company, announced its Q4 and full-year 2023 earnings on Wednesday after the market close. Ionis stock presently trades at around a value of $45.5 per share, and the market appears to have been largely unmoved by this latest…
DNY59 Investors Breathe a Sigh of Relief Post-Earnings, Look Forward to PHOENIX Data Amylyx Pharmaceuticals (NASDAQ:AMLX) has bounced back recently. Its stock is 50% higher since my rating downgrade (from “Strong Buy” to “Buy”) in November. The rating downgrade reflected increasing caution due to operational challenges, yet it still acknowledged the apparent undervaluation. After disappointing…
Nemes Laszlo/iStock via Getty Images Regeneron Pharmaceuticals (NASDAQ:REGN) has been one of my favorite growth stocks over the past several years. In fact, REGN is one of my “Top Ideas” in the Compounding Healthcare investing group on Seeking Alpha. Yet, I have never published a premium article covering Regeneron for Seeking Alpha despite all of…
Gilnature On Tuesday Feb 6, when Eli Lilly (LLY) announced their Q4 2023 report, the stocks of NASH (nonalcoholic steatohepatitis) drug developers, e.g. Madrigal Pharmaceuticals (NASDAQ:MDGL), Viking Therapeutics (VKTX), Akero Therapeutics (AKRO), Sagimet Biosciences (SGMT) etc., all come under selling pressure. The reason for the stock market sell-off appears to be the perception that LLY’s…
Daniel Christel/iStock via Getty Images Investment Overview Madrigal Pharmaceuticals (NASDAQ:MDGL), the Conshohocken, Pennsylvania based biotech, is the current leader of the “NASH Dash”, that is, the race to secure a first approval for a drug developed to treat nonalcoholic steatohepatitis, or “NASH” an advanced form of non-alcoholic fatty liver disease (“NAFLD”), where buildups of fat…
Ackun/iStock via Getty Images Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) have traded flat to somewhat lower since my November 2022 article and this was largely in line with what the average biotech stock was doing until early November of last year, the time when biotech stocks began to recover and Jazz’s share price made no progress….
Aksana Kavaleuskaya/iStock via Getty Images Aurinia Pharmaceuticals (NASDAQ:AUPH) markets Lupkynis (voclosporin) which was approved in January 2021 by the US Food and Drug Administration for the treatment of lupus nephritis. A recent preliminary update on Q4’23 and full-year 2023 financials provides an opportunity to look at where the company stands now. Is it finally time…
icarus666/Moment via Getty Images In my coverage of Arrowhead Pharmaceuticals (ARWR) last February, I noted that my primary problem with ARWR is a lack of focus. Just look at this pipeline: ARWR PIPELINE (ARWR WEBSITE) There are, if I am counting it right, some 16 programs in the clinic, and frankly, this is too much….
JLGutierrez Here’s a company with one approved product in one rare disease, another product just approved and about to be launched, revenue guidance for full year 2023 being “between $390 million and $395 million,” and little to no debt – but a market cap of just $1.7bn. We have seen preclinical companies with higher market…
monsitj Investment Overview Cambridge, Massachusetts-based Agios Pharmaceuticals (NASDAQ:AGIO) completed its Initial Public Offering over a decade ago in July 2013, raising ~$106m via the issuance of ~5.9m shares priced at $18 per share. The company developed and successfully won approval for the isocitrate dehydrogenase-1 (IDH1) inhibitor Tibsovo, in 2017, for patients with relapsed or refractory…
sanjeri Repetition of an argument proves your determination, not truth.”― Raheel Farooq Shares of rare disease concern Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) are trading some 60% higher after pricing a secondary in October 2023 at $30, owing to optimism regarding its pipeline. The company has seven rare disease assets in the clinic that could treat a…
onurdongel A Quick Take On Telomir Pharmaceuticals Telomir Pharmaceuticals (TELO) has filed proposed terms to raise $7 million from the sale of its common stock in an IPO, according to an amended SEC registration statement. The company is a pre-clinical stage biopharma firm developing treatments for age-related inflammatory conditions. I previously wrote about Telomir’s initial…
Ibrutinib, the BTK inhibitor which Corvus CEO Richard Miller was able to sell to AbbVie in 2015 while CEO of Pharmacyclics. ollaweila We first heard the name Corvus Pharmaceuticals (NASDAQ:CRVS) in a text message from Derek’s dad, asking our opinion on them. A cursory review of their company materials led us to conclude they were,…
ariya j/iStock via Getty Images Investment Overview I last covered Amneal Pharmaceuticals (NYSE:AMRX) for Seeking Alpha in a post published in March 2022. I gave the stock a “Buy” rating – at the time, Amneal stock traded at $4 per share, and although it had sunk as low as $1.3 per share by late May…
blackred Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) reported fiscal Q4 2023 results and provided a pipeline update this week. It was a generally upbeat update, with the company reporting positive preclinical toxicology results for ARO-RAGE and ARO-MMP7 with sufficient margins to allow the start of phase 2 trials in patients. However, that did not stop the stock…
mwellis/iStock via Getty Images My last article on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) in April rated the company a strong buy based on the revenue growth of Tavalisse (fostamatinib), expense reductions pushing the company towards profitability, and clinical catalysts including a trial of fostamatinib in COVID. This article looks at where RIGL stands now on its…
Virojt Changyencham/iStock via Getty Images Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has been making great progress with its pipeline, that’s because it was able to report some positive data from its phase 2 X-NOVA study, which used its drug XEN1101 for the treatment of patients with major depressive disorder [MDD]. Even though the primary endpoint of this…
AFT Pharmaceuticals Limited (OTCPK:AFTPF) Q2 2024 Earnings Conference Call November 22, 2023 4:00 PM ET Company Participants Hartley Atkinson – Managing Director Malcolm Tubby – Chief Financial Officer Conference Call Participants Soo Romanoff – Edison Group Matt Montgomerie – Forsyth Barr Christian Bell – Jarden Operator Good day. My name is Krista, and I’ll be…
Solskin A Quick Take On Telomir Pharmaceuticals, Inc. Telomir Pharmaceuticals, Inc. (TELO) has filed to raise $13.8 million in an IPO of its common stock, according to an SEC S-1 registration statement. The company is a pre-clinical stage biopharma developing treatment candidates for inflammatory disease conditions. Telomir Pharmaceuticals, Inc. is thinly capitalized, so the IPO…
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Jefferies Global Healthcare Conference Call November 14, 2023 3:30 AM ET Company Participants Stuart Arbuckle – Executive Vice President and Chief Operating Officer Conference Call Participants Michael Yee – Jefferies Michael Yee All right. Good morning, everybody. Thank you for joining us here on a beautiful morning session here at the…
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) UBS Biopharma Conference November 9, 2023 12:00 PM ET Company Participants Charlie Wagner – Executive Vice President & Chief Financial Officer David Altshuler – Chief Scientific Officer Conference Call Participants Colin Bristow – UBS Colin Bristow Good afternoon, and welcome to the UBS Biopharma Conference. I’m Colin Bristow, one of the…
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) UBS Biopharma Conference Call November 9, 2023 11:00 AM ET Company Participants Ryan Crowe – Vice President, Investor Relations Brook Jennings – Vice President, Immunology Marketing Conference Call Participants Colin Bristow – UBS Colin Bristow Well, good morning, and welcome to the UBS Biopharma Conference. I am Colin Bristow, one of…
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Brian Goff – Chief Executive Officer Cecilia Jones – Chief Financial Officer Tsveta Milanova – Chief Commercial Officer Sarah Gheuens – Chief Medical Officer Chris Taylor – Vice President, Investor Relations and Corporate Communications Conference Call Participants Divya…
koto_feja/E+ via Getty Images Company website Investment Thesis Rating Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Buy with 2-5 year target of $40 (3x upside) based on the discounted cash flow (“DCF”) valuation method. Steroids are used in 70% of patients with Duchenne’s muscular dystrophy, DMD, a debilitating neuromuscular disease, which is a 2 billion/year market and is…
PM Images Apellis Pharmaceuticals (NASDAQ:APLS), a standout player in the biotech sector, distinguishes itself with its novel C3 inhibitor technology, including their flagship compound, pegcetacoplan which has been branded into EMPAVELI (systemic) and SYVOVRE (intravitreal). Apellis has aimed pegcetacoplan to take on treating Paroxysmal Nocturnal Hemoglobinuria (PNH) and Geographic Atrophy (GA), with impressive data. In…
EHStock/iStock via Getty Images Investment Overview – Outstanding Start to 2023 For Apellis As SYFORVE Approved I last covered Apellis Pharmaceuticals (NASDAQ:APLS) for Seeking Alpha in a deep dive note at the end of January, giving the company a “buy” recommendation, when the company’s stock traded at ~$53 per share. What a roller-coaster ride the…
Cardiac amyloidosis OGphoto Alnylam logo We rate Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is based on the high probability of success for Vutrisiran, the company’s next-generation inverse RNA or RNAi candidate, in treating cardiac amyloidosis in the upcoming Phase 3 Helios-B…
DNY59/E+ via Getty Images At a Glance In the wake of Amneal Pharmaceuticals’ (NYSE:AMRX) Q2 2023 financials, we find a company at a crossroads, teetering between palpable growth and substantial indebtedness. Fueled by a diversified generics portfolio and burgeoning biosimilar contributions, Amneal posted a 7% YoY net revenue increase to $599M, flipping a $121M loss…
master1305/iStock via Getty Images Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company headquartered in Tarrytown that has played a key role in the fight against COVID-19. Since then, it has continued to rapidly expand its portfolio of medicines aimed at combating cancer, rare diseases, infectious diseases, and eye diseases. Under Leonard Schleifer’s leadership, the company…
gleitfrosch/iStock via Getty Images Topline Summary Actinium Pharmaceuticals (NYSE:ATNM) has had a bumpy year, with a lot of hype headed into 2023 only to have a big setback in March, and a slow descent ever since. Lack of clarity on data readouts has led to a lot of skepticism in ATNM at this time, with…
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) H.C. Wainwright 25th Annual Global Investment Conference Call September 12, 2023 4:30 PM ET Company Participants Jacqueline Shea – President and Chief Executive Officer Conference Call Participants Li Chen – H.C. Wainwright Li Chen Good afternoon, everyone, and welcome to H.C. Wainwright 25th Annual Global Investment Conference. My name is Li…
Inna Dodor/iStock via Getty Images Topline Summary It’s been a long time since I had a first look at Inovio Pharmaceuticals (NASDAQ:INO) on Seeking Alpha, and back then we were still mired deeply in COVID-19 uncertainty, and INO had made big strides in terms of valuation based on a DNA vaccine. I suggested you keep…
TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q2 2023 Results Conference Call August 15, 2023 11:00 AM ET Company Participants Corey Davis – IR, LifeSci Advisors Dr. Harlan Weisman – CEO Dr. Zamaneh Mikhak – Chief Medical Officer Kirk Coleman – CFO Conference Call Participants Jonathan Aschoff – ROTH MKM Justin Walsh – JonesTrading Vernon Bernardino – H.C….